Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Therapeutics Inc (NASDAQ:MRNA) stock moved lower on Thursday after the drugmaker's weak full-year sales forecast and a significant loss for the third quarter overshadowed better-than-expected revenue. For 3Q, Moderna's revenue fell from $3.4 billion in the same period in 2022 to $1.8 billion mainly due to decreased COVID-19 vaccine sales.

Moderna stock plummets on 3Q loss and weak sales guidance

Moderna on Thursday said it expected 2023 revenue of at least $6 billion, a decline reflecting weaker demand for COVID-19 vaccines this year, but that it would return to sales growth in 2025 and break even the following year.

Moderna revenue tops expectations, expects to return to sales growth in 2025

Moderna Inc. on Thursday reported a much wider-than-expected third quarter loss and reined in its full-year sales outlook as it resizes its pandemic-era manufacturing capacity and aims to break even in 2026.

Moderna posts wider-than-expected loss, reins in full-year outlook

Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billion Spikevax U.S. market share to date increased to 45% from 36% in 2022 Company anticipates 2024 revenue of approximately $4 billion and return to growth in 2025 Company has significantly improved future cost of sales by resizing its manufacturing capacity, contributing to a third quarter net loss of $3.6 billion, primarily driven by mostly non-cash charges of $3.1 billion related to resizing and a tax valuation allowance Company's late-stage pipeline has six Phase 3 programs Company expects to break even in 2026 through product launches and disciplined investment CAMBRIDGE, MA / ACCESSWIRE / November 2, 2023 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2023. "Through this quarter, we demonstrated our ability to increase share in the U.S. market, and we now expect this year's vaccination rate to be similar to last fall," said Stéphane Bancel, Chief Executive Officer of Moderna.

Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates

Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2023.

Exploring Analyst Estimates for Moderna (MRNA) Q3 Earnings, Beyond Revenue and EPS

Moderna should hit the lower end of its sales target for this year as it only needs to tap a small portion of the private market with its COVID vaccine to reach that goal, according to industry analysts.

Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say

New partnership will harness Moderna's mRNA rapid-response platform, clinically validated during the COVID-19 pandemic, to accelerate epidemic and pandemic vaccine development First project will enable rapid pre-clinical testing of antigen designs for high-risk viral families, to advance global outbreak readiness CAMBRIDGE, MA / ACCESSWIRE / October 30, 2023 / The Coalition for Epidemic Preparedness Innovations (CEPI) and Moderna, Inc. (NASDAQ:MRNA) have entered into a strategic partnership that will harness Moderna's mRNA platform to accelerate the development of vaccines against viral disease outbreaks that threaten global health. The work undertaken as part of this partnership could expand the infectious disease targets for mRNA vaccine technology and strengthen pandemic preparedness and public health efforts in alignment with the 100 Days Mission , a global goal to compress vaccine development timelines to 100 days.

CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission

Moderna, the world leader in mRNA vaccines, has seen its revenues collapse due to waning Covid severity and global immunity. Its stock price is close to a three-year low. However, the company pipeline is rich and has new treatments (Merck-Moderna Keytruda combination, CMV, RVS, and Flu) in phase 3 with significant revenue expectations within four years. High expenses will be required to fund this future growth but the large cash and equivalent position seems sufficient to cope with the situation.

Moderna: Looking Beyond Covid, The Pipeline Is Promising

Albemarle

Comerica

Dollar General

Estee Lauder

Enphase Energy

Etsy

Illumina

KeyCorp

Paramount Global

Insulet

SolarEdge Technologies

Investors fearing a brutal stock market crash are still waiting with dread. But it's already arrived for a group of battered S&P 500 stocks.

The Dreaded Market Crash Is Already Here For 14 Stocks

CAMBRIDGE, MA / ACCESSWIRE / October 26, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as one of the top employers in the global biopharmaceutical industry in Science and Science Careers' 2023 Top Employers Survey for the ninth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with respect, and social responsibility.

Moderna Named a Top Employer by Science for Ninth Consecutive Year

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline

VeriSign

Apple

Automatic Data Processing

AutoZone

Domino's Pizza

Fortinet

Home Depot

IDEXX Laboratories

KLA-Tencor

Lam Research

Mastercard

Mettler-Toledo

O'Reilly Automotive

Philip Morris

QUALCOMM

Texas Instruments

Waters

YUM! Brands

There is no easy way to select individual stocks. Measures of financial quality can highlight companies that are worth a closer look, but a decision to commit money must also take into consideration both recent developments and a look ahead.

Among the S&P 500, these 20 companies have made the best use of investors' money

SPDR S&P Regional Banking ETF

LVMH Moet Hennessy Louis Vuitton

Pfizer

PNC Financial Services

Polestar Automotive Holding UK PLC

Teladoc

Truist Financial

Tesla

VinFast Auto Ltd

Tax-loss selling may occur earlier this year, instead of the during usual time of selling pressure in late December. DataTrek suggests a list of stocks that may bounce back in November that we discuss. FMC Corporation, SolarEdge Technologies, Moderna, KeyCorp, and The Estee Lauder Companies are stocks to avoid due to weak performance and market conditions.

5 Stocks To Sell Before Tax-Loss Season Begins

Moderna Inc. investors enjoyed a rare rally Tuesday as shares of the biotechnology company headed for their first gain in two weeks.

Moderna's stock snaps record losing streak as Cathie Wood's ETF boosts stake by more than $4 million

Moderna Therapeutics Inc (NASDAQ:MRNA) has teamed up with Texas-headquartered private precision medicine and molecular science firm Caris Life Sciences for a multi-year partnership to advance mRNA-based oncology therapeutics. The companies said Tuesday that through this strategic agreement, Moderna will leverage Caris' library of de-identified, multi-modal data solutions derived from whole exome sequencing, whole transcriptome sequencing and protein analyses along with claims data to enhance development strategies for Moderna's oncology pipeline, including by optimizing clinical trial design, discovering novel biomarkers, and characterizing resistance mechanisms.

Moderna and Caris Life Sciences partner to develop mRNA oncology therapeutics

Moderna's earnings come out next month, and concerns are growing that they might not be all that strong. Revenue will decline sharply this year and it wouldn't be surprising if the company trims its forecast.

Moderna Stock Hasn't Been This Cheap Since 2020: Is Now the Time to Buy?

mRNA-1083 is Moderna's first respiratory combination vaccine candidate to enter a Phase 3 trial Phase 3 initiation follows data from a Phase 1/2 trial where mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company has multiple programs in Phase 3 development across several areas, including respiratory diseases, latent viruses, and oncology CAMBRIDGE, MA / ACCESSWIRE / October 24, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant has been dosed in a Phase 3 study of the Company's combination vaccine candidate against influenza and COVID-19 (mRNA-1083) in the U.S. The trial is expected to enroll approximately 8,000 adults in the Northern Hemisphere. The Phase 3 study will evaluate the immunogenicity, safety, and reactogenicity of mRNA‐1083 as compared with active control, co‐administered licensed influenza and SAR‐CoV‐2 vaccines in two independent age‐group sub‐study cohorts involving 4,000 adults 65 years and older and 4,000 adults 50 to

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19

Partnership enables Moderna to leverage Caris' vast library of de-identified, multi-modal data and analytics capabilities to accelerate precision medicine and the delivery of novel medicines to patients IRVING, Texas , Oct. 24, 2023 /PRNewswire/ -- Caris Life Sciences ®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced a new agreement with Moderna (NASDAQ:MRNA) in support of Moderna's oncology and novel therapeutics initiatives. Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics Through this multi-year agreement, Moderna will leverage Caris' vast library of de-identified, multi-modal data solutions derived from whole exome sequencing, whole transcriptome sequencing and protein analyses along with claims data to enhance development strategies for Moderna's oncology pipeline, including facilitation of optimal clinical trial design, discovery of novel biomarkers and characterization of resistance mechanisms.

Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics

Johnson & Johnson

Kenvue

Vertex Pharmaceuticals

Instead of focusing on investing for a particular market environment, consider stocks that generally may grow over time. It's a good idea to balance your investments across stocks that offer growth and safety.

The Best Stocks to Invest $5,000 In Right Now

Shares of Moderna Inc. were in danger of breaking their record for consecutive declines as investors express increasing caution over slowing sales of COVID vaccines.

Moderna's stock suffering record losing streak as ‘investor caution remains high' over COVID vaccine sales

Medtronic

Novo Nordisk

With a few exceptions, healthcare stocks have had a rough go of it in 2023. The Standards and Practices (S&P) 500 Healthcare Index is down 5% year to date, versus a 13% increase in the benchmark S&P 500 index.

3 Healthcare Stocks to Invest in for a Big Shot of Gains

While Pfizer Inc. (NYSE: PFE) was literally printing money during the Covid pandemic, those days are gone.

Pfizer and Moderna Stock Wrecked as Covid Vaccine Sales Dry Up

Amid dimming immediate prospects, the solar sector's long-term resilience could light the way for patient investors. Moderna's post-pandemic journey unveils the stark reality of biotech's boom-and-bust cycle.

Is It Time to Buy the S&P 500's 3 Worst-Performing Stocks This Year?

BioNTech SE

Novavax

Novavax NVAX, -5.56% stands out as a stark reminder of the biotech sector's faltering steps in 2023. Once renowned for its Nuvaxovid COVID-19 vaccine, the Maryland-based company is now grappling with financial issues, reflecting the broader challenges that continue to plague the pharmaceutical sector this year.

Biotech stocks are in a post-pandemic slump and recovery in 2024 is questionable

AMC Entertainment

United Continental Hlds

The stock market appears to be entering choppy waters as the year winds down. Between high inflation, unpredictable interest rates and an increasingly frightful geopolitical landscape, risk factors abound.

News for Moderna Stock (MRNA)